Inhibiton Therapeutics' Researcher to Present at American Association for Cancer Research Annual MeetingCENTENNIAL, Colo.--(BUSINESS WIRE)--Apr 10, 2008 - Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that the principal researcher for its ICA-1 compound, Dr. Mildred Acevede-Duncan, will present an abstract of the ICA-1 compound at the American Association for Cancer Research ("AACR") Annual Meeting in San Diego, California on April 14, 2008. The Company's abstract has been scheduled for presentation in a Poster Session at the 2008 AACR Annual Meeting in San Diego and will be published in the 2008 Proceedings of the American Association for Cancer Research.
The ICA-1 compound has demonstrated more exacting specificity of protein kinase C-iota and not of proteins that are closely related to PKC-iota. These results demonstrate greater promise for the development of a targeted therapy. Research being funded by the Company has shown that the ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. This research has demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.
Previously announced laboratory testing has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells finding and that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64% and 53% of the neuroblastoma cells when compared to control groups. The effects of ICA-1 on breast cancer cells have also obtained promising results. ICA-1 was effective in reducing the proliferation of MDA-MB-468 breast cancer cells by 83% compared to controls when incubated with the drug for 48 hours at clinical concentrations. For MCF-7 breast cancer cells, ICA-1 was effective in reducing the proliferation by 32% compared to controls when treated with the drug for 24 hours.
These results indicate that ICA-1 has promising results for further in-vitro studies as well as future in-vivo studies for the potential treatment of both neuroblastoma and breast cancer.
Inhibiton Therapeutics, Inc. is a nominally capitalized development-stage company focused on biotechnology research, development and potential commercialization of technologies and products for new cancer therapeutic agents and cancer-fighting drugs called targeted therapies. The initial focus of the Company's research is a protocol to investigate the effect of PKC isozymes on the regulation of various cancer cells including brain and breast cancer. Inhibiton began funding this research in September 2004.
The statements included in this press release concerning predictions of economic performance and management's plans and objectives constitute forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Any statement containing words such as "believes," "anticipates," "plans" or "expects" and other statements which are not historical facts contained in this release are forward-looking, and these statements involve risks and uncertainties and are based on current expectations. Consequently, actual results could differ materially from the expectations expressed in these forward-looking statements. Reference is made to the Company's filings with the Securities and Exchange Commission for a more complete discussion of such risks and uncertainties.
Inhibiton Therapeutics, Inc.
Thomas B. Olson, 303-796-8949
Posted: April 2008